Hovory o zdraví aneb Naslouchejme pacientům

PhDr. Lucie Klůzová Kráčmarová

Psychiatr. praxi. 2016;17(3):83  

The most common cause of death of psychiatric patients: We should not be afraid to treat it

prof. MUDr. Eva Králíková, CSc., MUDr. Lenka Štěpánková, Ph.D., MUDr. Erika Kalinová, MUDr. Zuzana Provazníková, MUDr. Bc. Kristina Sadílková

Psychiatr. praxi. 2016;17(3):88-91 | DOI: 10.36290/psy.2016.024  

Smoking related diseases are the leading cause of death among psychiatric patients. Effective treatment for tobacco dependence exists: it involves both interventions aimed at changing smoking stereotypes and search for nonsmoking solutions in combination with pharmacotherapy. First-line drugs are nicotine replacement therapy, bupropion and varenicline, currently the most effective one. Among psychiatric patients, so far the fear of neuropsychiatric side effects prevented broader application of varenicline. However, they have now been definitively refuted EAGLES large study that involved more than 8,000 smokers, of whom over 4,000 with psychiatric diagnosis....

Pharmacoresistant depression - what is the next step?

měli bychom zhodnotit diagnostické aspekty, hlavně komorbiditu a adekvátnost dosavadní léčby včetně adherence.

Psychiatr. praxi. 2016;17(3):92-95 | DOI: 10.36290/psy.2016.025  

Pharmacoresistant depression (treatment resistant depression, TRD) is associated with a higher suicidal risk of suicides and poor prognosis. Its management is a challenge. Before using the recommended strategies for TRD i.e. switch to another antidepressant, augmentation and combination of antidepressant, we should evaluate the diagnosis, mainly comorbidity and adequacy of previous treatment including adherence. Frequently used strategies such as augmentation and combinations have all disadvantages of polytherapy. An interesting option for TRD is monotherapy with multimodal/multifunctional antidepressants, aiming at several molecular targets...

A new nomenclature for psychotropic agents (Neuroscience-based Nomenclature)

MUDr. Bc. Libor Ustohal, Ph.D.

Psychiatr. praxi. 2016;17(3):98-102 | DOI: 10.36290/psy.2016.026  

The article presents a proposal for a new psychopharmacological nomenclature introduced by leading persons of international neuropsychopharmacological societies. The aim of this nomenclature, marked as Neuroscience-based Nomenclature (NbN), is to classify psychotropic agents by their pharmacological profile. It was developed to provide more rational choice of medication by its mechanism of action. The last version of this nomenclature is focused on pharmacological domains and modes/mechanisms of action. NbN also includes four additional dimensions: approved indication, efficacy and side effects, practical notes and neurobiology.

Aripiprazole in the treatment of bipolar disorder - its use in the clinical practice

MUDr. Sylva Racková, Ph.D.

Psychiatr. praxi. 2016;17(3):104-107 | DOI: 10.36290/psy.2016.027  

Aripiprazole is atypical antipsychotik (partial agonist of D2 and 5-HT1A and antagonist of 5-HT2A receptors). Aripiprazole is effective in the short and longterm treatment of bipolar affective disorder. We demonstrate on 3 case reports of bipolar patients when is possible to use aripiprazole in the treatment of this disorder.

Treatment of farmacoresistant depression in polymorbid patient

MUDr. Jana Komorousová, Ph.D.

Psychiatr. praxi. 2016;17(3):108-110 | DOI: 10.36290/psy.2016.028  

Case report presents the treatment of patients with type 2 diabetes who suffered from depression and whose psychological state after several years of unsuccessful treatment significantly improved with a combination of agomelatine and venlafaxine. Thanks to this medication the patient was improved in both psychological state and metabolic state - significantly decreased body weight and glycated hemoglobin, which is for treatment of diabetes desirable. Case report shows the importance to treat patients for sufficiently long period (if treatment well tolerated) untill the therapeutical effect land. Furthermore, agomelatine appeared to be suitable for...

Studie VIVALDI (Valdoxan Improves Depressive Symptoms and Normalizes Circadian Rhythms)

prof. MUDr. Pavel Mohr, Ph.D.,

Psychiatr. praxi. 2016;17(3):112-114  

Analýza podskupin neintervenční studie VIVALDI: Agomelatin u dříve neléčených pacientů, v kombinované léčbě a po změně léčby. Int J Psychiatry Clin Pract 2014; 18: 86-96.

doc. MUDr. Jiří Masopust, Ph.D.,

Psychiatr. praxi. 2016;17(3):115  

Group CBT therapy for patients with anxiety and depressive disorders experience from practice

Mgr. Roman Pešek, Mgr. Sandra Gembčíková, Mgr. Hana Kučová

Psychiatr. praxi. 2016;17(3):117-122 | DOI: 10.36290/psy.2016.031  

The article describes the practice of group cognitive behavioral therapy (CBT) in Psychosomatická klinika in Prague. Short-term outpatient CBT group is intended for patients with disorders from spectrum of neurotic disorders, anxiety disorders and moderate depression. The structure of the sessions is mentioned and the experience with commonly used cognitive-behavioral methods (like cognitive restructuring or therapeutic letters) in group settings are described. Several problems are mentioned and illustrated in one short case study. In the end, patients’ feedback is stated, and hypothetical causes why some patients do not have sufficient benefit...